Studies on a series of milnacipran analogs containing a heteroaromatic group as potent norepinephrine and serotonin transporter inhibitors

Bioorganic and Medicinal Chemistry Letters

Volumn 18, Issue 11, 2008, Pages 3230-3235

  Vickers, Troy ^a   Dyck, Brian ^a   Tamiya, Junko ^a   Zhang, Mingzhu ^a   Jovic, Florence ^a   Grey, Jonathan ^a   Fleck, Beth A ^a   Aparicio, Anna ^a   Johns, Michael ^a   Jin, Liping ^a   Tang, Hui ^a   Foster, Alan C ^b   Chen, Chen ^a  

^a Neurocrine Bioscience   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

Clearance; Lipophilicity; Metabolic stability; Milnacipran; Monoamine transporter inhibitor; Potency

Indexed keywords

MILNACIPRAN;

ANIMAL CELL; AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG ELIMINATION; DRUG POTENCY; DRUG SYNTHESIS; HUMAN; HUMAN CELL; LIPOPHILICITY; NONHUMAN; RAT; STRUCTURE ACTIVITY RELATION;

COMBINATORIAL CHEMISTRY TECHNIQUES; CYCLOPROPANES; HUMANS; MOLECULAR STRUCTURE; NOREPINEPHRINE; NOREPINEPHRINE PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN PLASMA MEMBRANE TRANSPORT PROTEINS; SEROTONIN UPTAKE INHIBITORS; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 44149106378     PISSN: 0960894X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.bmcl.2008.04.045     Document Type: Article

References (27)

1. Iversen L. Br. J. Pharmacol. 147 (2006) S82
2. Frampton J.E., and Plosker G.L. CNS Drugs 21 (2007) 581
3. Leventhal L., Smith V., Hornby G., Andree T.H., Brandt M.R., and Rogers K.E. J. Pharmacol. Exp. Ther. 320 (2007) 1178
4. Preskorn S.H. Reboxetine: J. Psychiatr. Pract. 10 (2004) 57
5. Krell H.V., Leuchter A.F., Cook I.A., and Abrams M. Psychosomatics 46 (2005) 379
6. Mochizucki D. Hum. Psychopharmacol. 19 (2004) S15
7. Bisserbe J.C. Int. Clin. Psychopharmacol. 17 (2002) S43
8. Owens M.J., Morgan W.N., Plott S.J., and Nemeroff C.B. J. Pharmacol. Exp. Ther. 283 (1997) 1305
9. Rooks D.S. Curr. Opin. Rheumatol. 19 (2007) 111
10. Leo R.J., and Brooks V.L. Curr. Opin. Investig. Drugs 7 (2006) 637
11. Calculated Log D values were 1.2 for milnacipran and 3.7 for duloxetine using ACD software.
12. Puozzo C., and Leonard B.E. Int. Clin. Psychopharmacol. 11 (1996) 15
13. Puozzo C., Panconi E., and Deprez D. Int. Clin. Psychopharmacol. 17 (2002) S25
14. Puozzo C., Lens S., Reh C., Michaelis K., Rosillon D., Deroubaix X., and Deprez D. Clin. Pharmacokinet. 44 (2005) 977
15. Bonnaud B., Cousse H., Mouzin G., Briley M., Stenger A., Fauran F., and Couzinier J.P. J. Med. Chem. 30 (1987) 318
16. Vaishnavi S.N., Nemeroff C.B., Plott S.J., Rao S.G., Kranzler J., and Owens M.J. Biol. Psychiatry 55 (2004) 320
17. Roggen H., Kehler J., Stensbol T.B., and Hansen T. Bioorg. Med. Chem. Lett. 17 (2007) 2834
18. Chen C., Dyck B., Fleck B.A., Foster A.C., Grey J., Jovic F., Mesleh M., Phan K., Tamiya J., Vickers T., and Zhang M. Bioorg. Med. Chem. Lett. 18 (2008) 1346
19. Tamiya J., Dyck B., Zhang M., Jovic F., Grey J., Vickers T., Phan K., Fleck B.A., Foster A.C., and Chen C. Bioorg. Med. Chem. Lett. 18 (2008) 3328
20. Doyle M.P., and Wu W. Adv. Synth. Catal. 343 (2001) 299
21. Shuto S., Ono S., Hase Y., Kamiyama N., Takada H., Yamasihita K., and Matsuda A. J. Org. Chem. 61 (1996) 915
22. Owens M.J., Morgan W.N., Plott S.J., and Nemeroff C.B. J. Pharmacol. Exp. Ther. 283 (1997) 1305 For experimental detail, see WO 07098356
23. 50 values reported by Roggen for the synaptosomal uptake inhibition, R-5: 19 nM (NET), 190 nM (SERT) and 10,000 nM (DAT); S-5: 410 nM (NET), 250 nM (SERT), 10,000 nM (DAT). See Ref. 17.
24. Guo Z., Zhu Y.F., Gross T.D., Tucci F.C., Gao Y., Moorjani M., Connors Jr. P.J., Rowbottom M.W., Chen Y., Struthers R.S., Xie Q., Saunders J., Reinhart G., Chen T.K., Bonneville A.L., and Chen C. J. Med. Chem. 47 (2004) 1259
25. Linnet K., and Ejsing T.B. Eur. Neuropsychopharmacol. 18 (2008) 157
26. 2OS·HCl), calcd: C 55.89%, H 7.04%, N, 9.31%, S 10.66%; found: C 55.90%, H 7.21%, N 9.18%, S 10.59%.
27. The compound (50 μM) was incubated at 37 °C for 2 h in human liver microsomes (0.5 mg/mL P450 proteins) or human hepatocytes (2.0 million cells/mL).